Cobben David C P, van der Laan Bernard F A M, Maas Bram, Vaalburg Willem, Suurmeijer Albert J H, Hoekstra Harald J, Jager Pieter L, Elsinga Philip H
PET Center, Groningen University Hospital, PO Box 30.001, 9700 RB Groningen, The Netherlands.
J Nucl Med. 2004 Feb;45(2):226-31.
The feasibility of (18)F-3'-fluoro-3'-deoxy-L-thymidine PET (FLT PET) for detecting laryngeal cancer was investigated and compared with (18)F-FDG PET.
Eleven patients diagnosed with or strongly suspected of having recurrent laryngeal cancer and 10 patients with histologically proven primary laryngeal cancer underwent attenuation-corrected (18)F-FLT PET imaging 60 min after injection of a median of 213 MBq (range, 175-400 MBq) (18)F-FLT and attenuation-corrected (18)F-FDG PET imaging 90 min after injection of a median of 340 MBq (range, 165-650 MBq) (18)F-FDG. All patients were staged by endoscopy and CT according to the Union Internationale Contre la Cancer TNM staging system. All patients underwent biopsy of the laryngeal area after imaging. Lesions seen on (18)F-FDG PET and (18)F-FLT PET were compared with histopathologic results. Mean SUVs, maximum SUVs, and tumor-to-nontumor (TNT) ratios were calculated for (18)F-FLT and (18)F-FDG. Wilcoxon nonparametric testing was used for comparison of (18)F-FDG with (18)F-FLT uptake. The Spearman correlation coefficient was used to correlate mean SUVs, maximum SUVs, and TNT ratios of (18)F-FDG PET and (18)F-FLT PET. Two-tailed P values < 0.05 were considered significant.
(18)F-FDG PET and (18)F-FLT PET detected laryngeal cancer correctly in 15 of 17 patients. One lesion judged as positive on (18)F-FDG PET turned out to be normal tissue. Of 2 lesions judged as positive on (18)F-FLT PET, 1 turned out to be inflammation and the other to be normal tissue. Maximum SUVs were 3.3 (range, 1.9-8.5) for (18)F-FDG and 1.6 (range, 1.0-5.7) for (18)F-FLT (P < 0.001). Mean SUVs were 2.7 (range, 1.5-6.5) for (18)F-FDG and 1.2 (range, 0.8-3.8) for (18)F-FLT (P < 0.001). TNT was 1.9 (range, 1.3-4.7) for (18)F-FDG and 1.5 (range, 1.1-3.5) for (18)F-FLT (P < 0.05).
The numbers of laryngeal cancers detected with (18)F-FLT PET and (18)F-FDG PET were equal. In laryngeal cancer, the uptake of (18)F-FDG is higher than that of (18)F-FLT.
研究了¹⁸F-3'-氟-3'-脱氧-L-胸腺嘧啶正电子发射断层显像(FLT PET)用于检测喉癌的可行性,并与¹⁸F-氟代脱氧葡萄糖正电子发射断层显像(¹⁸F-FDG PET)进行比较。
11例诊断为或高度怀疑患有复发性喉癌的患者以及10例经组织学证实的原发性喉癌患者,在注射¹⁸F-FLT(注射剂量中位数为213 MBq,范围175 - 400 MBq)60分钟后接受衰减校正的¹⁸F-FLT PET显像,并在注射¹⁸F-FDG(注射剂量中位数为340 MBq,范围165 - 650 MBq)90分钟后接受衰减校正的¹⁸F-FDG PET显像。所有患者均根据国际抗癌联盟TNM分期系统通过内镜和CT进行分期。所有患者在显像后均接受喉部区域活检。将¹⁸F-FDG PET和¹⁸F-FLT PET上所见病变与组织病理学结果进行比较。计算¹⁸F-FLT和¹⁸F-FDG的平均标准摄取值(SUV)、最大SUV以及肿瘤与非肿瘤(TNT)比值。采用Wilcoxon非参数检验比较¹⁸F-FDG与¹⁸F-FLT摄取情况。使用Spearman相关系数对¹⁸F-FDG PET和¹⁸F-FLT PET的平均SUV、最大SUV以及TNT比值进行相关性分析。双侧P值<0.05被认为具有统计学意义。
¹⁸F-FDG PET和¹⁸F-FLT PET在17例患者中的15例中正确检测出喉癌。1例在¹⁸F-FDG PET上被判定为阳性的病变结果为正常组织。在¹⁸F-FLT PET上被判定为阳性的2个病变中,1个为炎症,另1个为正常组织。¹⁸F-FDG的最大SUV为3.3(范围1.9 - 8.5),¹⁸F-FLT为1.6(范围1.0 - 5.7)(P<0.001)。¹⁸F-FDG的平均SUV为2.7(范围1.5 - 6.5),¹⁸F-FLT为1.2(范围0.8 - 3.8)(P<0.001)。¹⁸F-FDG的TNT为1.9(范围1.3 - 4.7),¹⁸F-FLT为1.5(范围1.1 - 3.5)(P<0.05)。
¹⁸F-FLT PET和¹⁸F-FDG PET检测出的喉癌数量相同。在喉癌中,¹⁸F-FDG的摄取高于¹⁸F-FLT。